PHOENIX — Anaphylaxis accounted for 15% of the adverse reports from clinicians after mRNA vaccinations for COVID-19, according to a late-breaking abstract at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Anaphylaxis appeared more common following vaccination with Pfizer-BioNTech and among white women. Although most of these patients received emergency treatment, few required hospitalization and none were treated in the ICU, results showed.
Evidence-based information about side effects can combat vaccine hesitancy in the wake of hypersensitivity reactions